Authors: Matthew James Verheyden, Medical Student, University of Notre Dame, Sydney, NSW, Australia; Claudia Hadlow, Medical Student, University of Notre Dame, Sydney, NSW, Australia. DermNet Editor in Chief: Adjunct A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy edited by Gus Mitchell/Maria McGivern. August 2019.
Chilblain lupus erythematosus (LE) is a rare variant of chroniccutaneous LE originally described by Jonathan Hutchinson in 1888 [1].
The term ‘chilblain’ is derived from Anglo-Saxon terms ‘chill’ referring to ‘cold’ and ‘blegen’, which is a synonym for ‘sore’.
Chilblain lupus
Lupus chilblains
Lupus chilblains
Who gets chilblain lupus erythematosus?
Chilblain LE is an under-reported entity. In a 2008 review, the authors stated that 70 cases have been reported in the literature. It mainly occurs in adults but can occur at any age [2].
Chilblain LE occurs as both a sporadic and inherited condition. Sporadic cases are the most common and occur predominantly in middle-aged women [3], while familial chilblain LE presents in early childhood [4].
Associations between chilblain LE and anorexia nervosa, intestinal lymphoma, and pregnancy have been described in the literature.
What causes chilblain lupus erythematosus?
The pathogenesis of the sporadic form of chilblain LE remains unknown [2].
It is believed a cold stimulus provokes vasoconstriction or microvascular injury with occlusion of the capillary bed and diminished circulation, leading to hyperviscosity and stasis of the skin, which is exacerbated by reduced blood temperature [2,3].
These pathophysiological changes in the flow and microvasculature may be aggravated by immunological anomalies (eg, rheumatoid factor or autoantibodies).
In those with a family history or onset of chilblain LE in childhood, the condition may be a result of a mutation in the TREX1 or SAMHD1genes [5].
TREX1 is a gene located on chromosome 3 that encodes a nuclearprotein with a role in DNA repair and proofreading for DNA polymerase.
SAMHD1 is a gene located on chromosome 20 that encodes a host restriction nuclease with a role in the innate immune response.
These mutations in TREX1 and SAMHD1 are inherited in an autosomal-dominant manner [4,6]. Heterozygous mutation (mutation of one allele) in these genes lead to the accumulation of nucleic acids (eg, double-stranded DNA, RNA–DNA duplexes).
TREX1 mutations have also been described in other conditions related to microvascular endothelialdysfunction, such as dominant retinal vasculopathy and cerebral leukodystrophy.
What are the clinical features of chilblain lupus erythematosus?
Chilblain LE begins as red or dusky purple patches, papules, and plaques that are initiated or exacerbated by exposure to cold and moisture in a cool climate. The lesions are often pruritic and painful.
The common sites involved are the fingers, toes, heels, and soles of the feet. Less frequently, the lesions may be present on the nose, ears, palms, knuckles, elbows, knees, and lower legs.
People living in regions with warmer and drier climates may not develop typical chilblains.
In some circumstances, chilblains may represent lupus pernio with pre-existing LE rather than as chilblain LE [7]. Although the two entities are clinically similar and both are associated with systemic disease (sarcoidosis and systemic lupus erythematosus, respectively), the prognosis and treatment regimens are distinct [7].
What are the complications of chilblain lupus erythematosus?
Follow-up is advised for those with features of SLE (eg, malarrash).
How is chilblain lupus erythematosus diagnosed?
The Mayo Clinic diagnostic criteria for the diagnosis of chilblain LE comprises two major and four minor criteria [8]. To diagnose chilblain LE, both major criteria and at least one minor criterion need to be demonstrated.
Mayo Clinic diagnostic major criteria
The major criteria for chilblain LE are:
Lesions in acral locations induced by exposure to cold or any decrease in temperature
Lesions persisting beyond the colder months, positive antinuclear antibody tests, and concomitant features of the American College of Rheumatology criteria for SLE distinguish chilblain LE from idiopathicchilblains [9].
What is the differential diagnosis for chilblain lupus erythematosus?
Dermatomyositis can cause nail fold erythema, telangiectasia, and nailfoldinflammation similar to chilblain LE. Other clinical features of dermatomyositis include:
What is the treatment for chilblain lupus erythematosus?
General measures
Protection from the cold should be emphasised and may include:
Avoidance of cold and moist environments where possible
Ensuring that the home and workplace are well insulated and heated
Wearing gloves, thick woollen socks, and comfortable protective footwear
Soaking hands in warm water to warm them up throughout the day
Engaging in physical activity to maintain central body temperature.
Smokingcessation should also be encouraged, due to the vasoconstrictive effects of nicotine.
Medications
Medication may be necessary for patients with recalcitrant lesions and for secondary bacterial skin infections. A therapeutic approach has been proposed based on the level of evidence of the therapies in chilblain LE [2].
Patients with chilblain LE have successfully been treated in certain circumstances by excision and repair using a full-thickness graft derived from an unaffected area.
What is the outcome for chilblain lupus erythematosus?
The majority of patients respond well to symptomatic treatment.
In those with the sporadic form of chilblain LE, 18% of individuals will eventually develop SLE; there is no evidence of progression to SLE in cases of familial chilblain LE.
References
Hutchinson J. Harveian lectures on lupus. Br Med J 1888; 1: 113–8. DOI: 10.1136/bmj.1.1412.113. PubMed Central
Hedrich CM, Hauck FH, Sallmann S, et al. Chilblain lupus erythematosus — a review of literature. Clin Rheumatol 2008; 27: 947–54. DOI: 10.1007/s10067-008-0942-9. PubMed
Doutre MS, Beylot C, Beylot J, Pompougnac E, Royer P. Chilblain lupus erythematosus: report of 15 cases. Dermatology 1992; 184: 26–8. DOI: 10.1159/000247494. PubMed
Lee-Kirsch MA, Chowdhury D, Harvey S, et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med 2007; 85: 531–7. DOI: 10.1007/s00109-007-0199-9. PubMed
Tüngler V, Silver RM, Walkenhorst H, Günther C, Lee-Kirsch MA. Inherited or de novo mutation affecting aspartate 18 of TREX1 results in either familial chilblain lupus or Aicardi–Goutières syndrome. Br J Dermatol 2012; 167: 212–4. doi: 10.1111/j.1365-2133.2012.10813.x. PubMed
Lee-Kirsch MA, Gong M, Schulz H, et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet 2006; 79: 731–7. DOI: 10.1086/507848. PubMed Central
Arias-Santiago SA, Girón-Prieto M-S, Callejas-Rubio J-L, Fernández-Pugnaire M-A, Ortego-Centeno N. Lupus pernio or chilblain lupus?: two different entities. Chest 2009; 136: 946–7. DOI: 10.1378/chest.09-1005. PubMed
Su WP, Perniciaro C, Rogers RS 3rd, White JW Jr. Chilblain lupus erythematosus (lupus pernio): clinical review of the Mayo Clinic experience and proposal of diagnostic criteria. Cutis 1994; 54: 395–9. PubMed
Viguier M, Pinquier L, Cavelier-Balloy B, et al. Clinical and histopathologic features and immunologic variables in patients with severe chilblains: a study of the relationship to lupus erythematosus. Medicine 2001; 80: 180–8. DOI: 10.1097/00005792-200105000-00004. PubMed